bioAffinity Technologies Secures $1.2M Through Private Placement

bioAffinity Technologies, Inc. ( (BIAF) ) just unveiled an announcement.

On August 13, 2025, bioAffinity Technologies, Inc. entered into a securities purchase agreement with institutional and accredited investors to issue and sell Series B Convertible Preferred Stock and warrants in a private placement, raising approximately $1.2 million in gross proceeds. The company also executed a warrant inducement transaction with an existing investor, which involved exercising existing warrants at a reduced price and issuing new warrants, resulting in additional proceeds of $253,000. The proceeds from these transactions are intended for working capital and general corporate purposes, potentially strengthening the company’s financial position and supporting its operational goals.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Spark’s Take on BIAF Stock

According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.

The score reflects significant financial challenges and poor valuation metrics. However, recent positive corporate developments, including international patent approvals and successful product tests, provide potential growth opportunities. Technical indicators suggest stability in the short term, but financial instability and Nasdaq compliance issues present notable risks.

To see Spark’s full report on BIAF stock, click here.

More about bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. is a biotechnology company focused on developing noninvasive tests for the early detection of cancer, specifically lung cancer. Their primary product, CyPath® Lung, is a noninvasive test marketed as a Laboratory Developed Test (LDT) by their subsidiary, Precision Pathology Laboratory Services.

Average Trading Volume: 7,189,187

Technical Sentiment Signal: Sell

Current Market Cap: $7.8M

Learn more about BIAF stock on TipRanks’ Stock Analysis page.